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Abstract
Introduction: Tumoral calcinosis is a rare and benign condition characterized by massive subcutaneous soft tissue
deposits of calcium phosphate predominantly around large joints.
Case presentation: Familial tumoral calcinosis was present in two members of a Han Chinese family, namely, the
son and daughter. The 14-year-old son had the first operation on his right sole of the foot at the age of six, and
then experienced subsequent surgeries at a lesion in his right sole of the foot and left hip, respectively. The 16-
year-old daughter underwent her first operation at the age of six in her left gluteal region, and subsequent
surgeries were performed due to recurrence at the same lesion. Pathologic diagnoses of surgical specimens in
both of the patients were reported as tumoral calcinosis. The laboratory results showed hyperphosphatemia with
normal levels of serum calcium and alkaline phosphatase. Only surgical treatment was performed in both patients
with satisfactory prognosis.
Conclusion: This is the first report of Chinese familial tumoral calcinosis. The etiopathogenisis and treatment are
discussed.
Introduction
Tumoral calcinosis (TC) was first described by Inclan
[1] in 1943 as slow growing, progressive masses usually
found adjacent to large joints such as hips, shoulders
and elbows. The masses are hard and painless. Recur-
rence tends to be observed at the same location subse-
quent to inadequate resection. Further identification is
based on the pathogenesis. We describe the first two
cases of familial TC in Chinese siblings, and present
their clinical and pathological features.
Case Presentations
Case one
A 14-year-old Han Chinese boy presented with an eight-
year history of TC. He first noticed a painful mass on
the bottom of his right foot at the age of six, and mass
resection was performed. Then an operation was con-
ducted for a mass that developed on the bottom of his
left foot at the age of eight. A mass first occurred on his
left hip at the age of 12. This mass excised and diag-
nosed on pathology as a tendon calcification tumor.
After that, a recurrent mass on his lateral left hip was
observed. On physical examination, the mass was firm,
sessile, with a clear edge and normal skin temperature,
and measured 4 × 5 cm. Distal circulation, muscle
strength, motion, and sensation of the left lower limb
were all intact. His serum phosphorus level (2.7 mmol/
L) was higher than the upper normal range (0.97 to 1.61
mmol/L). Calcium and alkaline phosphatase levels were
normal. Radiography revealed a multilobular, calcified
mass around the left hip joint (Figure 1). The nodular
mass was excised and had dimensions of 5 by 4 by 2
cm. The section was grey or light-yellow, hard, with a
gravel appearance. The center section had a honeycomb
appearance, and contained yellow and white pasty calci-
fication. Pathological examination confirmed the diagno-
sis of TC (Figures 2 and 3). It showed a globular bluish
nodule containing amorphous and homogenous sub-
stances, suggesting deposits of calcium. No fibrous cap-
sule was observed surrounding the nodule, but fibrous
connective tissue was found between nodules. The
nodule was surrounded by infiltrated inflammatory cells,
with a clear edge and a foreign body-type granuloma-
tous reaction. No recurrence was observed after a 14-
month follow-up period.
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Case two
A 16-year-old Han Chinese girl presented with a 10-year
history of TC. Several resections had been performed
due to recurrence. On physical examination, a large
mass was found on her left hip and buttock. It was
hard, fixed, nodular, and with a chalky effusion from fis-
tula of involved skin. The motion of left hip articulation
was intact. Her serum phosphorus level was higher than
the upper normal range. Calcium and alkaline phospha-
tase were normal. Radiography revealed multilobular
calcification near the left hip articulation and within the
soft tissue of her buttock. The function of her skeleton
and articulation nearby was normal. Pathological exami-
nation confirmed the diagnosis of TC. No similar
complaint was made by other family members. The par-
ents were first cousins.
Discussion
TC is a rare disorder of mineral metabolism character-
ized by tumor-like periarticular deposition of calcium
phosphate. There are two major clinical categories of
TC based on its pathogenesis: familial tumoral calcinosis
(FTC) with two subtypes: hyperphosphatemic FTC
(HFTC) and normophosphatemic FTC (NFTC) based
on serum phosphate status [2]; and secondary tumoral
calcinosis. The diagnosis is confirmed mainly by medical
history, physical examination, laboratory tests, radiologi-
cal examination, and histology. The imaging features of
FTC were explored by Jose et al. [3]. Our two cases are
consistent with the features of HFTC. HFTC is due to
mutations in three genes: fibroblast growth factor-23
(FGF23) [4], coding for a potent phosphaturic protein;
KL [5] encoding Klotho, serving as a co-receptor for
FGF23; and GALNT3 [6], encoding a glycosyltransferase
responsible for FGF23 O-glycosylation. Recently, FTC is
considered a different manifestation (allelic variants) of
the same disease as the hyperostosis-hyperphosphatemia
syndrome (HHS), having similar biochemical abnormal-
ities and caused by mutation of the GALNT3 gene [7].
NFTC is characterized by the absence of metabolic
abnormalities. It was found to be associated with the
absence of functional SAMD9, a putative tumor sup-
pressor and anti-inflammatory protein [8].
Resection of the mass is the preferred treatment for
TC in a relatively stable stage in which the mass is cap-
sulated, but recurrence is common. Phosphate depletion
(aluminum hydroxide and acetazolamide) and low-phos-
phate, low-calcium diets, have a varied effect on FTC,
but the benefits are limited [9]. In our cases, only
Figure 1 A 14-year-old boy with a multilobular, calcific mass
around his left hip joint.
Figure 2 A histologic section of the tissue showing calcium
deposits.
Figure 3 Fibrous bands were found to intersect between
nodules. Amorphous calcareous debris is shown.
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surgical treatment was performed considering the disad-
vantage of drug regimens on adolescents. Further study
should be conducted to research the epidemiology and
genomics of familial tumoral calcinosis in Asian families
Conclusion
In summary, our presentation is the first report regard-
ing FTC in Chinese patients. Imaging and pathological
examinations are the commonly used diagnostic proce-
dures. Further study will focus on epidemiology in Asia,
the mutations in genomics and the variance between
Asian and Caucasian patients. Although the pathogen-
esis of the calcification process in TC is still controver-
sial, surgical removal is the mainstay treatment with a
satisfactory prognosis.
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